Fulcrum therapeutics to participate in upcoming september conferences

Cambridge, mass., aug. 27, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (the “company”) (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings at the following conferences:
FULC Ratings Summary
Quant
FULC Quant Ranking
Sector
Industry
Quant Rating
Quant Score